New Zealand Biochips Market (2025-2030)
The New Zealand Biochips Market was valued at $82.4 Million in 2025 and projected to reach to $113.2 Million by 2030, representing a compound annual growth rate of 6.5%. New Zealand's biochips market demonstrates steady expansion through 2030, driven by increasing healthcare investments and technological adoption in diagnostic applications.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
New Zealand Biochips Market Trends and Insights
- Valued at USD 82.4 million in 2025, New Zealand is experiencing steady expansion driven by advances in diagnostic and therapeutic applications.
- The market in New Zealand is projected to reach USD 113.2 million by 2030, reflecting a compound annual growth rate of 6.5% over the forecast period. New Zealand's biochips sector benefits from the country's strong healthcare infrastructure and increasing investment in precision medicine and personalized diagnostics.
- The adoption of biochip technologies in New Zealand is accelerating as healthcare providers seek innovative solutions for disease detection, drug development, and patient monitoring.
- New Zealand's regulatory environment and research capabilities continue to support market growth, positioning the nation as an emerging hub for biochip innovation within the broader Asia Pacific region..
Key Market Statistics
- CAGR (2025-2030) 6.5% CAGR
- Market Size, 2025 ~USD 82.4 Million
- Forecast, 2030 ~USD 113.2 Million
- Country New Zealand
New Zealand Biochips Market Overview
Market Valuation :
New Zealand's biochips market is valued at USD 82.4 million in 2025, with projected growth to USD 113.2 million by 2030, representing a steady 6.5% CAGR within the Asia Pacific region.
Growth Trajectory :
New Zealand's biochips market is expanding at 6.5% CAGR, outpacing some regional peers while maintaining a measured growth pace compared to the global 8.8% CAGR, indicating localized market maturation.
Diagnostic & Therapeutic Focus :
The New Zealand market is driven by advances in diagnostic and therapeutic biochip applications, reflecting increasing adoption in clinical laboratories, research institutions, and personalized medicine initiatives across the country.
Asia Pacific Integration :
New Zealand's biochips market operates as a growing segment within the broader Asia Pacific healthcare technology landscape, benefiting from regional supply chains and collaborative research networks.
New Zealand Biochips Market Dynamics
- The country's advanced healthcare infrastructure and research capabilities support market growth, with particular momentum in personalized medicine and point-of-care testing solutions.
- Healthcare providers and diagnostic laboratories are progressively integrating biochip technologies to enhance clinical efficiency and patient outcomes. The 6.5% CAGR reflects New Zealand's measured but consistent market development, supported by government healthcare initiatives and private sector innovation.
- While growing slower than the global average, the market benefits from high healthcare spending per capita and strong regulatory frameworks.
- Continued investment in biotechnology research and development, coupled with increasing awareness of biochip applications among medical professionals, positions New Zealand for sustained market growth through the forecast period..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- New Zealand's biochips market is valued at USD 82.4 million in 2025 and is expected to grow to USD 113.2 million by 2030.
- New Zealand demonstrates a 6.5% CAGR, reflecting steady but moderate growth compared to global expansion rates.
- New Zealand's healthcare infrastructure and precision medicine initiatives are key drivers of biochip market adoption.
- New Zealand is emerging as a regional innovation hub, supported by strong regulatory frameworks and research capabilities.
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
New Zealand Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
Target Audience
- Healthcare Device Manufacturers : Manufacturers seeking to expand biochip product portfolios in New Zealand need localized market data to understand demand patterns, regulatory requirements, and distribution opportunities in this growing healthcare market.
- Diagnostic Laboratory Operators : Laboratory managers and operators require insights into biochip adoption trends and technological advancements to make informed procurement decisions and enhance diagnostic capabilities for New Zealand patients.
- Healthcare Investment Firms : Investment professionals evaluating opportunities in New Zealand's healthcare technology sector need accurate market sizing and growth forecasts to assess the viability and ROI potential of biochip-related ventures.
- Biotech Research Institutions : Research organizations and universities in New Zealand need market intelligence to align biochip research initiatives with commercial opportunities and secure funding for innovation projects with clear market demand.
- Healthcare Policy & Government Bodies : Government agencies and health policy makers require comprehensive market data to develop informed healthcare technology strategies, funding allocations, and regulatory frameworks supporting New Zealand's biochips sector growth.
Key Companies in the New Zealand Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Reasons to Buy this Report
- Localized Market Intelligence : Gain country-specific insights into New Zealand's USD 82.4 million biochips market with detailed analysis of local growth drivers, regulatory environment, and competitive landscape distinct from broader Asia Pacific trends.
- Accurate Forecast Data : Access precise projections showing New Zealand's market expansion to USD 113.2 million by 2030 at 6.5% CAGR, enabling accurate business planning and investment decisions for the New Zealand healthcare sector.
- Strategic Market Positioning : Understand New Zealand's unique position within Asia Pacific healthcare technology, identifying opportunities for market entry, partnerships, and expansion strategies tailored to the local healthcare ecosystem.
- Application-Specific Insights : Discover detailed analysis of diagnostic and therapeutic biochip applications gaining traction in New Zealand, including adoption rates among hospitals, laboratories, and research institutions.
- Competitive Advantage : Leverage comprehensive New Zealand market data to benchmark against competitors, identify market gaps, and develop targeted strategies for capturing share in this growing healthcare technology segment.
Frequently asked questions
What is the current size of New Zealand's biochips market?
New Zealand's biochips market is estimated at USD 82.4 million in 2025, based on verified market data.
What is the projected market size for New Zealand's biochips sector by 2030?
New Zealand's biochips market is forecast to reach USD 113.2 million by 2030, representing growth of approximately 37% over the five-year period.
What is the CAGR for New Zealand's biochips market?
New Zealand's biochips market is projected to grow at a compound annual growth rate of 6.5% from 2025 to 2030.
What factors are driving growth in New Zealand's biochips market?
Key drivers include New Zealand's advanced healthcare infrastructure, increasing investment in precision medicine, growing adoption of personalized diagnostics, and supportive regulatory frameworks.
How does New Zealand's biochips market compare to the global market?
New Zealand's 6.5% CAGR is slightly below the global average of 8.8%, indicating steady regional growth with potential for acceleration as adoption increases.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- UK Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- Netherlands Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
